Govt allows use of low-cost steroid dexamethasone for COVID-19 treatment

By: |
Published: June 27, 2020 3:09 PM

The updated protocol includes the advice to use dexamethasone as an alternative choice to methylprednisolone for managing moderate to severe cases of COVID-19.

covid 19, coronavirus update, dexamethasone
According to the revised ‘Clinical Management Protocols for COVID-19’, dexamethasone which is already used in treating lung infections. (File Photo for representation)

Coronavirus Treatment Medicine: An inexpensive, widely used steroid ‘dexamethasone’was included in the treatment protocols for COVID-19 patients in moderate to severe stages of illness among other therapeutic measures by the Union health ministry on Saturday.

The updated protocol includes the advice to use dexamethasone as an alternative choice to methylprednisolone for managing moderate to severe cases of COVID-19. The change has been made after considering the latest available evidence and expert consultation, the ministry said.

Also Read: Coronavirus India Latest Updates

According to the revised ‘Clinical Management Protocols for COVID-19’, dexamethasone which is already used in treating lung infections besides in a wide range of conditions for its anti-inflammatory and immunosuppressant effects can be used as an alternative to methylprednisolone which already existed in the treatment guidelines.

The health ministry on June 13 had also allowed the use of antiviral drug ‘remdesivir’ for restricted emergency use and off-label application of tocilizumab, a drug that modifies the immune system or its functioning, and convalescent plasma for treating COVID-19 patients in moderate stage of the illness as an ‘investigational therapy’.

It also recommended hydroxychloroquine in patients during the early course of the disease and not on critically ill patients.

The use of these drugs continues to be included in the revised treatment protocols under the ‘investigational therapy’.

Also Read: Immune cells involved in protection against COVID-19 identified: Study

The revised treatment protocols for moderate cases advised considering methylprednisolone 0.5 to 1 mg/kg or dexamethasone 0.1 to 0.2 mg/kg for three days, preferably within 48 hours of admission or if oxygen requirement is increasing and if inflammatory markers are increased. The duration of administration should be reviewed as per clinical response.

For patients having respiratory distress requiring mechanical ventilation, both non- invasive and invasive, the ministry said methylprednisolone 1 2mg/kg/day or dexamethasone 0.2 to 0.4 mg/kg per day should be considered for 5-7 days in two divided doses, if not given already.

“Note that a larger dose of glucocorticoid will delay the removal of coronavirus due to immunosuppressive effects,” the treatment protocols stated.

The revised treatment protocols were issued as India’s COVID-19 tally raced past the five-lakh mark on Saturday with the biggest single-day surge of 18,552 cases while the death toll climbed to 15,685 with 384 fatalities, the updated figure at 8 am showed.

According to WHO, the corticosteroid dexamethasone was tested in hospitalised patients with COVID-19 in the United Kingdom’s national clinical trial ‘RECOVERY’ and was found to have benefits for critically ill patients.

According to preliminary findings shared with WHO, for patients on ventilators, the treatment was shown to reduce mortality by about one-third, and for patients requiring only oxygen, mortality was cut by about one-fifth.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Health ministry says Covid-19 to increase healthcare spend by a fifth during FY22-FY26
2Ebola spreading in western Congo with nearly 50 confirmed cases: WHO
3COVID-19: Delhi records 1,246 new cases, lowest in last 35 days; LNJP to have capital’s second plasma bank